Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas

Brief summary (registry, in English)

The goal of this study is to better understand biological characteristics of non-rhabdomyosarcoma soft tissue sarcomas (NRSTS), a rare group of cancers that affect children, adolescents, and young adults. Researchers also aim to identify factors that could help predict how the disease will behave and respond to treatment. The main questions it aims to answer are: * Can advanced molecular analyses improve the classification and diagnosis of NRSTS? * Can blood- and tumor-based biomarkers help predict outcomes and detect relapse earlier? * Can researchers identify biological features that may guide future personalized treatments? Participants aged 0 to 25 years with a recent diagnosis of NRSTS will take part in the prospective study. Researchers will collect archived tumor samples and blood samples during routine follow-up (approximately every 3 to 4 months) and will analyze these samples using advanced laboratory techniques. Clinical information will also be collected over a follow-up period of up to 4 years. 150 participants will be enrolled in the prospective part from 28 investigating centers across France. Tumor samples already collected as part of your care, together with blood samples taken during follow-up visits, will be stored for future researches.

What you commit to

• Study type: Observational
• Planned participants: 150
• From Dec 2026 to the primary completion date, Dec 2034
• 28 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children, teenagers and young adults aged 0 to 25 years with a newly found non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). Tumor and blood samples are studied for biological features.

Age

0 to 25 years

Sex

All sexes can join.

Disease stage

Intermediate or malignant NRSTS at first diagnosis, found within the last 3 months. The disease can be localized or metastatic.

Earlier treatment

Any treatment plan is allowed: observation, surgery, chemotherapy, radiotherapy or other systemic therapies.

Biomarker or test result

Archived tumor tissue must be available: at least 1 FFPE block or 1 HE slide with IHC slides.

Main reasons for not taking part

• NRSTS that has come back (relapse)
• Medical, psychological, social or geographic conditions that would make taking part or cooperating hard, in the investigator's opinion
• People deprived of their liberty or under guardianship
• No health insurance affiliation

Read by machine on 10 Nov 2026.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: - to 25 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (28)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details